| 1 | Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study | 1.3 | 9 | Citations (PDF) |
| 2 | Letter: Analysis of “Faecal Biomarkers for Diagnosis and Prediction of Disease Course in Treatment‐Naïve Patients With <scp>IBD</scp>”—Authors' Reply | 3.7 | 0 | Citations (PDF) |
| 3 | Human MAIT cell response profiles biased toward IL-17 or IL-10 are distinct effector states directed by the cytokine milieu | 7.5 | 26 | Citations (PDF) |
| 4 | Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review | 3.3 | 0 | Citations (PDF) |
| 5 | Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease | 2.5 | 6 | Citations (PDF) |
| 6 | Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis | 1.3 | 4 | Citations (PDF) |
| 7 | Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype | 1.3 | 8 | Citations (PDF) |
| 8 | Fecal Microbiome Reflects Disease State and Prognosis in Inflammatory Bowel Disease in an Adult Population-Based Inception Cohort | 2.9 | 3 | Citations (PDF) |
| 9 | Adult-onset inflammatory bowel disease and the risk of venous thromboembolism – a Swedish nationwide cohort study 2007–2021 | 1.7 | 4 | Citations (PDF) |
| 10 | Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort—an Epi-IBD cohort study | 1.3 | 3 | Citations (PDF) |
| 11 | Cancer incidence in patients with ulcerative colitis naïve to or treated with thiopurine and targeted therapies—a cohort study 2007 to 2022 with comparison to the general population | 1.3 | 7 | Citations (PDF) |
| 12 | 1200: SURGERY AS A TREATMENT OPTION FOR CROHN’S DISEASE: A NATIONWIDE COHORT STUDY | 0.9 | 0 | Citations (PDF) |
| 13 | Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations | 1.3 | 22 | Citations (PDF) |
| 14 | Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes | 1.3 | 9 | Citations (PDF) |
| 15 | Atherosclerosis as a Risk Factor of Inflammatory Bowel Disease: A Population-Based Case-Control Study | 0.7 | 16 | Citations (PDF) |
| 16 | Histologic Activity in Inflammatory Bowel Disease and Risk of Serious Infections: A Nationwide Study | 6.0 | 24 | Citations (PDF) |
| 17 | Eosinophilic esophagitis is associated with increased risk of later inflammatory bowel disease in a nationwide Swedish population cohort | 4.8 | 9 | Citations (PDF) |
| 18 | Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels | 1.7 | 2 | Citations (PDF) |
| 19 | Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study | 16.8 | 1 | Citations (PDF) |
| 20 | P1089 Disease characteristics at time of diagnosis of adult onset inflammatory bowel disease and the risk of venous thromboembolism in the modern era – A Swedish nationwide cohort study 2007-2021 | 1.3 | 0 | Citations (PDF) |
| 21 | Long-Term Risk of Myocarditis in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study in Sweden | 0.7 | 3 | Citations (PDF) |
| 22 | Histologic Remission in Inflammatory Bowel Disease and Female Fertility: A Nationwide Study | 0.9 | 14 | Citations (PDF) |
| 23 | Rectal Sensory and Compliance Testing: A Method Comparison Study between High-Resolution Anorectal Manometry and Barostat Investigations | 2.8 | 1 | Citations (PDF) |
| 24 | Spondyloarthritis in First-Degree Relatives and Spouses of Patients with Inflammatory Bowel Disease: A Nationwide Population-based Cohort Study from Sweden | 1.3 | 1 | Citations (PDF) |
| 25 | Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease | 2.1 | 7 | Citations (PDF) |
| 26 | Risk of heart failure in inflammatory bowel disease: a Swedish population-based study | 2.2 | 31 | Citations (PDF) |
| 27 | Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease | 13.7 | 18 | Citations (PDF) |
| 28 | Novel biomarker profiles to improve individual diagnosis and prognosis in patients with suspected inflammatory bowel disease: protocol for the Nordic inception cohort study (NORDTREAT) | 1.9 | 2 | Citations (PDF) |
| 29 | Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers | 0.7 | 13 | Citations (PDF) |
| 30 | Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with
IBD | 3.7 | 18 | Citations (PDF) |
| 31 | A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk | 3.7 | 8 | Citations (PDF) |
| 32 | The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study | 2.9 | 9 | Citations (PDF) |
| 33 | Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome | 1.3 | 44 | Citations (PDF) |
| 34 | Mucosal and Plasma Metabolomes in New-onset Paediatric Inflammatory Bowel Disease: Correlations with Disease Characteristics and Plasma Inflammation Protein Markers | 1.3 | 29 | Citations (PDF) |
| 35 | Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease | 1.3 | 17 | Citations (PDF) |
| 36 | Association of inflammatory bowel disease in first‐degree relatives with risk of colorectal cancer: A nationwide case‐control study in Sweden | 4.3 | 3 | Citations (PDF) |
| 37 | Long-term risk of inflammatory bowel disease after endoscopic biopsy with normal mucosa: A population-based, sibling-controlled cohort study in Sweden | 8.0 | 3 | Citations (PDF) |
| 38 | Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease | 2.1 | 10 | Citations (PDF) |
| 39 | Inflammatory Bowel Disease and Risk of Colorectal Polyps: A Nationwide Population-Based Cohort Study From Sweden | 1.3 | 5 | Citations (PDF) |
| 40 | Increasing Risk of Lymphoma Over Time in Crohn’s Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study | 6.0 | 20 | Citations (PDF) |
| 41 | Epidemiology, validation, and clinical characteristics of inflammatory bowel disease: the ABIS birth cohort study | 2.2 | 16 | Citations (PDF) |
| 42 | Long-term Risk of Stroke in Patients With Inflammatory Bowel Disease | 1.0 | 29 | Citations (PDF) |
| 43 | Mo1768 LONG-TERM RISK OF STROKE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED, SIBLING-CONTROLLED COHORT STUDY 1965-2019 | 0.9 | 0 | Citations (PDF) |
| 44 | Sa1818 LONG-TERM RISK OF ARRHYTHMIAS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED, SIBLINGCONTROLED COHORT STUDY 1965-2019 | 0.9 | 0 | Citations (PDF) |
| 45 | Sa1771 ATHEROSCLEROSIS AS A RISK FACTOR FOR IBD; A POPULATION-BASED CASE-CONTROL STUDY | 0.9 | 0 | Citations (PDF) |
| 46 | 690 STATIN USE AND RISK OF COLORECTAL CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE | 0.9 | 0 | Citations (PDF) |
| 47 | Mo1775 INFLAMMATORY BOWEL DISEASE AND RISK OF COLORECTAL POLYPS: A NATIONWIDE POPULATION-BASED COHORT STUDY FROM SWEDEN | 0.9 | 0 | Citations (PDF) |
| 48 | Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus | 2.5 | 9 | Citations (PDF) |
| 49 | Increasing healthcare costs in inflammatory bowel disease 2007–2020 in Sweden | 3.7 | 15 | Citations (PDF) |
| 50 | Statin use and risk of colorectal cancer in patients with inflammatory bowel disease | 8.2 | 28 | Citations (PDF) |
| 51 | Long-term risk of arrhythmias in patients with inflammatory bowel disease: A population-based, sibling-controlled cohort study | 8.0 | 20 | Citations (PDF) |
| 52 | Mortality in patients with Crohn’s disease in Örebro, Sweden 1963–2010 | 1.7 | 5 | Citations (PDF) |
| 53 | Probability of Stoma in Incident Patients With Crohn’s Disease in Sweden 2003-2019: A Population-based Study | 2.9 | 29 | Citations (PDF) |
| 54 | Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study | 6.0 | 48 | Citations (PDF) |
| 55 | Detailed Transcriptional Landscape of Peripheral Blood Points to Increased Neutrophil Activation in Treatment-Naïve Inflammatory Bowel Disease | 1.3 | 26 | Citations (PDF) |
| 56 | P342 Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium | 1.3 | 0 | Citations (PDF) |
| 57 | IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus | 6.0 | 21 | Citations (PDF) |
| 58 | Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2 | 1.3 | 47 | Citations (PDF) |
| 59 | A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014 | 3.7 | 57 | Citations (PDF) |
| 60 | Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease | 2.1 | 21 | Citations (PDF) |
| 61 | Age determines the risk of familial inflammatory bowel disease—A nationwide study | 3.7 | 32 | Citations (PDF) |
| 62 | Association Between Inflammatory Bowel Disease and Spondyloarthritis: Findings from a Nationwide Study in Sweden | 1.3 | 20 | Citations (PDF) |
| 63 | Association of Celiac Disease and Inflammatory Bowel Disease: A Nationwide Register-Based Cohort Study | 0.7 | 29 | Citations (PDF) |
| 64 | Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register | 4.8 | 41 | Citations (PDF) |
| 65 | Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study | 3.7 | 13 | Citations (PDF) |
| 66 | Normal gastrointestinal mucosa at biopsy and subsequent cancer risk: nationwide population-based, sibling-controlled cohort study | 2.9 | 4 | Citations (PDF) |
| 67 | Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study | 8.2 | 22 | Citations (PDF) |
| 68 | Women’s Earnings are more Affected by Inflammatory Bowel Disease than Men’s: A Register-Based Swedish Cohort Study | 1.3 | 9 | Citations (PDF) |
| 69 | Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn’s Disease | 2.9 | 25 | Citations (PDF) |
| 70 | Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease | 1.3 | 69 | Citations (PDF) |
| 71 | Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study | 3.2 | 25 | Citations (PDF) |
| 72 | Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register – a validation study | 1.7 | 30 | Citations (PDF) |
| 73 | Association Between Inflammatory Bowel Disease and Psychiatric Morbidity and Suicide: A Swedish Nationwide Population-Based Cohort Study With Sibling Comparisons | 1.3 | 67 | Citations (PDF) |
| 74 | Hepatobiliary Cancer Risk in Patients with Inflammatory Bowel Disease: A Scandinavian Population-Based Cohort Study | 1.1 | 27 | Citations (PDF) |
| 75 | Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Prediction and Prevention of Inflammatory Bowel Disease | 1.3 | 66 | Citations (PDF) |
| 76 | Inflammatory bowel disease and risk of severe COVID‐19: A nationwide population‐based cohort study in Sweden | 4.8 | 47 | Citations (PDF) |
| 77 | Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn’s disease (PROSE): a 16-week follow-up | 1.7 | 8 | Citations (PDF) |
| 78 | Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection | 2.3 | 17 | Citations (PDF) |
| 79 | P284 Drug survival and remission rates in ustekinumab treated ulcerative colitis: Results from the Swedish Inflammatory Bowel Disease register (SWIBREG) | 1.3 | 1 | Citations (PDF) |
| 80 | Reply | 6.0 | 0 | Citations (PDF) |
| 81 | Systemic Inflammation in Preclinical Ulcerative Colitis | 0.9 | 124 | Citations (PDF) |
| 82 | Technological readiness and implementation of genomic‐driven precision medicine for complex diseases | 7.3 | 27 | Citations (PDF) |
| 83 | Predictors of drug survival: A cohort study comparing anti‐tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register | 3.7 | 13 | Citations (PDF) |
| 84 | Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG | 1.7 | 10 | Citations (PDF) |
| 85 | Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects
ex vivo
in murine intestinal tissue | 1.7 | 33 | Citations (PDF) |
| 86 | Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002–2017 | 1.7 | 21 | Citations (PDF) |
| 87 | Crohn’s Disease Is Associated With Activation of Circulating Innate Lymphoid Cells | 2.9 | 28 | Citations (PDF) |
| 88 | Restorative Surgery Is More Common in Ulcerative Colitis Patients With a High Income: A Population-Based Study | 1.7 | 12 | Citations (PDF) |
| 89 | Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers | 3.7 | 33 | Citations (PDF) |
| 90 | Prognostic Biosignatures at Ileocecal Resection: Hope or Reality? | 1.3 | 0 | Citations (PDF) |
| 91 | Letter: vedolizumab or a second anti‐TNF—no difference in efficacy for primary biologic failures with IBD. Authors' reply | 3.7 | 0 | Citations (PDF) |
| 92 | Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study | 62.1 | 420 | Citations (PDF) |
| 93 | A User’s Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease | 6.0 | 12 | Citations (PDF) |
| 94 | P740 Age determines the risk of familial IBD: A nationwide case–control study | 1.3 | 0 | Citations (PDF) |
| 95 | 762 INCREASED RISK OF SMALL BOWEL CANCER AND SMALL BOWEL CANCER DEATH IN INFLAMMATORY BOWEL DISEASE: A BINATIONAL POPULATION-BASED STUDY | 0.9 | 0 | Citations (PDF) |
| 96 | The use of 5‐aminosalicylate for patients with Crohn’s disease in a prospective European inception cohort with 5 years follow‐up – an Epi‐IBD study | 4.8 | 27 | Citations (PDF) |
| 97 | Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character) | 1.7 | 38 | Citations (PDF) |
| 98 | Genetic and shared environmental risk factors do not lead to eosinophil activation in healthy twins of IBD patients | 1.7 | 3 | Citations (PDF) |
| 99 | Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden | 3.7 | 57 | Citations (PDF) |
| 100 | Untargeted metabolomics profiling and hemoglobin normalization for archived newborn dried blood spots from a refrigerated biorepository | 3.0 | 29 | Citations (PDF) |
| 101 | The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register | 1.7 | 62 | Citations (PDF) |
| 102 | Age, Inflammation, and Disease Location Are Critical Determinants of Intestinal Expression of SARS-CoV-2 Receptor ACE2 and TMPRSS2 in Inflammatory Bowel Disease | 0.9 | 77 | Citations (PDF) |
| 103 | Inflammatory bowel disease and pancreatic cancer: a Scandinavian register‐based cohort study 1969‐2017 | 3.7 | 38 | Citations (PDF) |
| 104 | Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990–2014 | 0.3 | 72 | Citations (PDF) |
| 105 | Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease | 0.9 | 227 | Citations (PDF) |
| 106 | Whole Blood Profiling of T-cell-Derived microRNA Allows the Development of Prognostic models in Inflammatory Bowel Disease | 1.3 | 31 | Citations (PDF) |
| 107 | Depletion of erythropoietic miR-486-5p and miR-451a improves detectability of rare microRNAs in peripheral blood-derived small RNA sequencing libraries | 2.2 | 15 | Citations (PDF) |
| 108 | Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study | 22.8 | 141 | Citations (PDF) |
| 109 | Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study | 22.8 | 194 | Citations (PDF) |
| 110 | The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases | 11.4 | 91 | Citations (PDF) |
| 111 | OP08 Inflammatory bowel disease and risk of small bowel cancer: A binational population-based cohort study from Denmark and Sweden | 1.3 | 1 | Citations (PDF) |
| 112 | Inflammatory Bowel Disease and Parkinson’s Disease: A Nationwide Swedish Cohort Study | 2.9 | 153 | Citations (PDF) |
| 113 | Association of Childhood-Onset Inflammatory Bowel Disease With Risk of Psychiatric Disorders and Suicide Attempt | 8.5 | 104 | Citations (PDF) |
| 114 | Inflammatory Bowel Disease and Parkinson’s Disease: A Reply to Letter to the Editor of Shih-Wei Lai | 2.9 | 0 | Citations (PDF) |
| 115 | Swedish Inflammatory Bowel Disease Register (SWIBREG) – a nationwide quality register | 1.7 | 61 | Citations (PDF) |
| 116 | Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease | 1.7 | 19 | Citations (PDF) |
| 117 | OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM | 1.3 | 13 | Citations (PDF) |
| 118 | Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients | 1.7 | 65 | Citations (PDF) |
| 119 | Alterations in the relative abundance of Faecalibacterium prausnitzii correlate with changes in fecal calprotectin in patients with ileal Crohn’s disease: a longitudinal study | 1.7 | 17 | Citations (PDF) |
| 120 | Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development | 22.8 | 57 | Citations (PDF) |
| 121 | DOP27 Sequencing-based hematopoietic miRNA landscape reveals common and distinct features of autoimmune inflammatory phenotypes | 1.3 | 0 | Citations (PDF) |
| 122 | Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease | 16.5 | 173 | Citations (PDF) |
| 123 | Validating surgical procedure codes for inflammatory bowel disease in the Swedish National Patient Register | 3.1 | 40 | Citations (PDF) |
| 124 | The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis | 2.7 | 47 | Citations (PDF) |
| 125 | Work Loss Before and After Diagnosis of Crohn’s Disease | 2.9 | 27 | Citations (PDF) |
| 126 | Disease course of inflammatory bowel disease unclassified in a European population‐based inception cohort: An Epi‐IBD study | 2.5 | 31 | Citations (PDF) |
| 127 | Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci | 2.9 | 19 | Citations (PDF) |
| 128 | Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study | 1.3 | 149 | Citations (PDF) |
| 129 | Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study | 16.8 | 252 | Citations (PDF) |
| 130 | Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study | 16.8 | 26 | Citations (PDF) |
| 131 | Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study | 16.8 | 163 | Citations (PDF) |
| 132 | Simultaneous determination of perfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography–tandem mass spectrometry | 3.4 | 84 | Citations (PDF) |
| 133 | Gut Barrier Dysfunction—A Primary Defect in Twins with Crohn’s Disease Predominantly Caused by Genetic Predisposition | 1.3 | 38 | Citations (PDF) |
| 134 | P547 Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC) | 1.3 | 1 | Citations (PDF) |
| 135 | P812 Natural disease course of inflammatory bowel disease unclassified in a prospective European population-based inception cohort—the Epi-IBD cohort | 1.3 | 0 | Citations (PDF) |
| 136 | OP001 Gut barrier dysfunction: a primary defect in twins with Crohn’s disease predominantly caused by genetic predisposition | 1.3 | 12 | Citations (PDF) |
| 137 | P758 Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn’s disease (SVEAH CD) | 1.3 | 2 | Citations (PDF) |
| 138 | Development of an index to define overall disease severity in IBD | 16.8 | 142 | Citations (PDF) |
| 139 | Resilience to stress and risk of gastrointestinal infections | 0.3 | 4 | Citations (PDF) |
| 140 | Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden | 0.9 | 215 | Citations (PDF) |
| 141 | P166 Prognostic significance of eosinophil granule proteins in inflammatory bowel disease | 1.3 | 0 | Citations (PDF) |
| 142 | Mo1915 - The Impact of Thiopurines on the Natural History and Surgical Outcome of Ulcerative Colitis: A Cohort Study | 0.9 | 0 | Citations (PDF) |
| 143 | Differential clustering of fecal and mucosa‐associated microbiota in ‘healthy’ individuals | 1.6 | 35 | Citations (PDF) |
| 144 | Validating microscopic colitis (MC) in Swedish pathology registers | 1.7 | 43 | Citations (PDF) |
| 145 | Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) | 1.7 | 12 | Citations (PDF) |
| 146 | Sick Leave and Disability Pension in Prevalent Patients With Crohn’s Disease | 1.3 | 23 | Citations (PDF) |
| 147 | Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study | 1.3 | 31 | Citations (PDF) |
| 148 | Should we use vedolizumab as mono or combo therapy in ulcerative colitis? | 2.7 | 14 | Citations (PDF) |
| 149 | P707 Increasing abundance of faecalibacterium prausnitzii is associated with decreased intestinal inflammation in Crohn’s disease: A longitudinal study | 1.3 | 0 | Citations (PDF) |
| 150 | Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study | 3.7 | 51 | Citations (PDF) |
| 151 | 15 - Health Care Use, Work Loss, and Total Costs in Incident and Prevelant Ulcerative Colitis: Results from a Nationwide Study in Sweden | 0.9 | 0 | Citations (PDF) |
| 152 | Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis | 16.8 | 57 | Citations (PDF) |
| 153 | Stress resilience and the risk of inflammatory bowel disease: a cohort study of men living in Sweden | 1.9 | 39 | Citations (PDF) |
| 154 | Dynamics of the human gut microbiome in inflammatory bowel disease | 16.0 | 1,122 | Citations (PDF) |
| 155 | Cost-utility of biological treatment sequences for luminal Crohn’s disease in Europe | 1.4 | 28 | Citations (PDF) |
| 156 | Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort—An ECCO-EpiCom Study | 1.3 | 29 | Citations (PDF) |
| 157 | Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) | 1.7 | 113 | Citations (PDF) |
| 158 | Changes in medical management and colectomy rates: a population‐based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963‐2010 | 3.7 | 66 | Citations (PDF) |
| 159 | Fine-mapping inflammatory bowel disease loci to single-variant resolution | 37.9 | 600 | Citations (PDF) |
| 160 | Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG) | 1.7 | 170 | Citations (PDF) |
| 161 | Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time | 1.7 | 16 | Citations (PDF) |
| 162 | Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD | 2.3 | 4 | Citations (PDF) |
| 163 | Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles | 2.3 | 35 | Citations (PDF) |
| 164 | OP022 Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study | 1.3 | 6 | Citations (PDF) |
| 165 | P061 Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – IBD Character | 1.3 | 0 | Citations (PDF) |
| 166 | P788 Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease | 1.3 | 0 | Citations (PDF) |
| 167 | P695 The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort | 1.3 | 0 | Citations (PDF) |
| 168 | P694 Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort | 1.3 | 3 | Citations (PDF) |
| 169 | LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis | 3.8 | 33 | Citations (PDF) |
| 170 | A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition | 0.9 | 144 | Citations (PDF) |
| 171 | The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease | 3.7 | 71 | Citations (PDF) |
| 172 | A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis | 13.7 | 57 | Citations (PDF) |
| 173 | Heritability of non-HLA genetics in coeliac disease: a population-based study in 107 000 twins | 16.8 | 105 | Citations (PDF) |
| 174 | Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease – authors’ reply | 3.7 | 0 | Citations (PDF) |
| 175 | Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn’s Disease | 1.3 | 13 | Citations (PDF) |
| 176 | Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci | 25.2 | 753 | Citations (PDF) |
| 177 | The changing face of Crohn’s disease: a population-based study of the natural history of Crohn’s disease in Örebro, Sweden 1963–2005 | 1.7 | 40 | Citations (PDF) |
| 178 | Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study | 62.1 | 745 | Citations (PDF) |
| 179 | Functional Analyses of the Crohn’s Disease Risk Gene LACC1 | 2.3 | 32 | Citations (PDF) |
| 180 | Polymorphism in the NLRP3 inflammasome-associated EIF2AK2 gene and inflammatory bowel disease | 2.8 | 15 | Citations (PDF) |
| 181 | Mo1802 Intestinal Dysbiosis in Collagenous Colitis | 0.9 | 4 | Citations (PDF) |
| 182 | Physical Fitness in Adolescence and Subsequent Inflammatory Bowel Disease Risk | 2.7 | 42 | Citations (PDF) |
| 183 | Genetic variants inCDC42andNXPH1as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome | 16.8 | 57 | Citations (PDF) |
| 184 | Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease — An ECCO-EpiCom study☆ | 1.3 | 68 | Citations (PDF) |
| 185 | Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe — An ECCO-EpiCom study | 1.3 | 90 | Citations (PDF) |
| 186 | HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants | 25.2 | 188 | Citations (PDF) |
| 187 | Temporal trends in non-stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: A population-based retrospective study | 1.3 | 26 | Citations (PDF) |
| 188 | Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study | 1.3 | 23 | Citations (PDF) |
| 189 | Letter: the impact of smoking on clinical outcomes after endoscopic dilatation in Crohn's disease – authors’ reply | 3.7 | 0 | Citations (PDF) |
| 190 | Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease | 3.7 | 63 | Citations (PDF) |
| 191 | Letter: infliximab in severe ulcerative colitis – is it useful for all patients? Authors’ reply | 3.7 | 0 | Citations (PDF) |
| 192 | Endoscopic dilation is an efficacious and safe treatment of intestinal strictures in Crohn's disease | 3.7 | 134 | Citations (PDF) |
| 193 | Letter: endoscopic balloon dilatation or strictureplasty for stricturing Crohn's disease? Authors' reply | 3.7 | 0 | Citations (PDF) |
| 194 | Endoscopic Balloon Dilation of Intestinal Strictures in Crohn's Disease | 0.9 | 0 | Citations (PDF) |
| 195 | Association of
TNFSF15
polymorphism with irritable bowel syndrome | 16.8 | 116 | Citations (PDF) |
| 196 | Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 | 25.2 | 1,286 | Citations (PDF) |
| 197 | Genetics in twins with Crohnʼs disease: Less pronounced than previously believed? | 2.9 | 97 | Citations (PDF) |
| 198 | Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci | 25.2 | 2,446 | Citations (PDF) |
| 199 | A Pyrosequencing Study in Twins Shows That Gastrointestinal Microbial Profiles Vary With Inflammatory Bowel Disease Phenotypes | 0.9 | 1,010 | Citations (PDF) |
| 200 | Metabolomics Reveals Metabolic Biomarkers of Crohn's Disease | 2.3 | 464 | Citations (PDF) |
| 201 | No Association Between the Eczema Genes COL29A1 and IL31 and Inflammatory Bowel Disease | 2.9 | 3 | Citations (PDF) |
| 202 | Treatment of choice for acute severe steroid-refractory ulcerative colitis is Remicade | 2.9 | 12 | Citations (PDF) |
| 203 | Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohnʼs disease | 2.9 | 427 | Citations (PDF) |
| 204 | 113 Subclinical Inflammation Due to Environmental Exposure in Healthy Co-Twins to Twins with Inflammatory Bowel Disease | 0.9 | 0 | Citations (PDF) |
| 205 | Molecular analysis of the gut microbiota of identical twins with Crohn's disease | 9.1 | 423 | Citations (PDF) |
| 206 | M2080 Compound Polymorphisms in CARD8 and CIAS1 Predispose to Crohn's Disease in a Swedish Cohort | 0.9 | 0 | Citations (PDF) |
| 207 | W1182 Molecular Fingerprinting of the Gut Microbiota of Twins Reveals Differences According to Crohn's Disease | 0.9 | 1 | Citations (PDF) |
| 208 | Long-Term Colectomy Rate After Intensive Intravenous Corticosteroid Therapy for Ulcerative Colitis Prior to the Immunosuppressive Treatment Era | 0.7 | 71 | Citations (PDF) |
| 209 | Longitudinal concordance for clinical characteristics in a Swedish-Danish twin population with inflammatory bowel disease | 2.9 | 37 | Citations (PDF) |
| 210 | Environmental factors in inflammatory bowel disease: A co-twin control study of a Swedish-Danish twin population | 2.9 | 153 | Citations (PDF) |
| 211 | CARD15/NOD2 polymorphisms do not explain concordance of Crohn's disease in Swedish monozygotic twins | 2.5 | 17 | Citations (PDF) |
| 212 | Smoking as a possible explanation for the low concordance among twins with Ulcerative ColitisȁA population based study of environmental factors in a Danish-Swedish twin cohor | 0.9 | 1 | Citations (PDF) |
| 213 | Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics | 0.9 | 393 | Citations (PDF) |
| 214 | Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden | 16.8 | 37 | Citations (PDF) |
| 215 | Patients With Inflammatory Bowel Disease Are at Increased Risk of Interstitial Lung Diseases | 0.7 | 1 | Citations (PDF) |
| 216 | Environmental and Inflammatory Factors Drive Perinuclear‐Antineutrophil Cytoplasmic Antibodies (pANCA) in Ulcerative Colitis: A European Twin Study | 4.8 | 0 | Citations (PDF) |
| 217 | Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies | 2.9 | 2 | Citations (PDF) |
| 218 | First insights into microbial changes within an Inflammatory Bowel Disease Family Cohort study | 10.2 | 9 | Citations (PDF) |
| 219 | Association of histologic and clinical activity with major adverse cardiovascular events in patients with inflammatory bowel disease: A cohort study | 7.3 | 3 | Citations (PDF) |
| 220 | International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials | 1.3 | 4 | Citations (PDF) |
| 221 | Histologic Remission and Mortality in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study | 6.0 | 3 | Citations (PDF) |
| 222 | Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: a nationwide cohort study | 1.3 | 3 | Citations (PDF) |
| 223 | Incidence and Risk of Colorectal Dysplasia in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study | 6.0 | 1 | Citations (PDF) |
| 224 | Association of inflammatory bowel disease with cardiovascular disease, and the mediating role of inflammation: a matched-cohort study | 3.2 | 2 | Citations (PDF) |
| 225 | Heritability of Crohn’s disease and ulcerative colitis: a Swedish nationwide population-based twin study | 1.3 | 0 | Citations (PDF) |
| 226 | Sa1592 PSYCHIATRIC DISORDERS BEFORE AND AFTER INFLAMMATORY BOWEL DISEASE DIAGNOSIS: A NATIONWIDE COHORT STUDY IN SWEDEN 2007-2023 | 0.9 | 0 | Citations (PDF) |
| 227 | Mo1495 INCIDENCE AND RISK OF COLORECTAL DYSPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE COHORT STUDY | 0.9 | 0 | Citations (PDF) |
| 228 | Tu1621 EARLY COLECTOMY AND LONG-TERM RISK OF CARDIOMETABOLIC DISEASE IN ULCERATIVE COLITIS: A NATIONWIDE COHORT STUDY | 0.9 | 0 | Citations (PDF) |
